Upcoming AACR ‘24 Clinical Readouts

American Association for Cancer Research Annual Meeting 2024

New clinical data at AACR (FIG. 1 📸):

April 7, 2024

Replimune Group Inc. (NASDAQ: REPL)

Drug Name: RP1

Indication: Cutaneous squamous cell carcinoma

Trial Stage: Ph 1/2 

Kazia Therapeutics Limited (NASDAQ: KZIA) 

Drug Name: EVT801

Indication: Advanced Solid Tumors

Trial Stage: Ph 1 

April 8, 2024

Poseida Therapeutics, Inc. (NASDAQ: PSTX)

Drug Name: P-BCMA-ALLO1 

Indication: Multiple Myeloma

Trial Stage: Ph 1/2 

Drug Name: P-MUC1C-ALLO1

Indication: Ovarian cancer, Breast cancer

Trial Stage: Ph 1 

April 9, 2024

BeiGene (NASDAQ: BGNE)

Drug Name: Ociperlimab + tislelizumab 

Indication: limited stage-SCLC

Trial Stage: Ph 2 

Medicenna Therapeutics (NASDAQ: MDNA)

Drug Name: MDNA11  

Indication: Cold tumors

Trial Stage: Ph 1/2 

RAPT Therapeutics (NASDAQ: RAPT)

Drug Name: Tivumecirnon/FLX475 

Indication: Non-small cell lung carcinoma

Trial Stage: Ph 2 

Fusion Pharmaceuticals (NASDAQ: FUSN)

Drug Name: FPI-2265 

Indication: Prostate Cancer

Trial Stage: Ph 2

Purple Biotech (NASDAQ: PPBT)

Drug Name: NT219 

Indication: Head and neck squamous cell carcinoma

Trial Stage: Ph 1

Atossa Therapeutics (NASDAQ: ATOS)

Drug Name: (Z)-endoxifen 

Indication: Breast Cancer

Trial Stage: Ph 2

April 10, 2024

Lantern Pharma (NASDAQ: LTRN)

Drug Name: LP-284 

Indication: Non-Hodgkin's Lymphoma

Trial Stage: Ph 1

BioNTech (NASDAQ: BNTX)

Drug Name: BNT122 w/ atezolizumab and chemotherapy 

Indication: Pancreatic cancer

Trial Stage: Ph 1

Drug Name: BNT116 +/- cemiplimab

Indication: Non-small cell lung carcinoma

Trial Stage: Ph 1

FIG. 1. Upcoming data readouts at AACR '24

---

Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more

Article History:

RF & DV (04/04/24)